This market authorisation is part of a process including 15 countries in Europe. Azzalure ® will be commercialised in Spain by Galderma. Lausa...

Read more...

This market authorisation is part of a process including 15 countries in Europe. Azzalure ® will be commercialised in Germany by Galderma Laus...

Read more...

Lausanne (Switzerland) and Paris (France), 30 March 2009 – Galderma, the leading pharmaceutical company in dermatology, and Ipsen (Euronext: IPN), an ...

Read more...

First market authorisation of 15 for Azzalure ® in Europe Azzalure ® will be commercialised by Galderma Lausanne (Switzerland) and Paris (Fran...

Read more...

Fort Worth, TX – February 3, 2009 – Galderma Laboratories, L.P. today announced that the U.S. Food and Drug Administration (FDA) has approved Vectical™ (calcitriol) Ointment 3mcg/g, a unique vitamin D3 product for the treatment of mild-to-moderate plaque psoriasis in adults.

Read more...